Canada's new drug price rules pushed to next year

1 June 2020 - Canada's drug pricing agency said on Monday that new regulations aimed at lowering costs would come ...

Read more →

Tax payers paid to develop remdesivir but will have no say when Gilead sets the price

27 May 2020 - Critics say government deserves more credit for tens of millions in public money spent to develop coronavirus ...

Read more →

Australia avoids 'risky business' of coronavirus vaccine sweepstakes

27 May 2020 - Australia is avoiding huge financial risks by staying out of the global sweepstakes on coronavirus vaccines. ...

Read more →

FDA grants priority review of Nucala for patients with hypereosinophilic syndrome

27 May 2020 - An approval would give Nucala a third indication in an eosinophil driven disease. ...

Read more →

Trump tries to convince voters he’s lowered drug prices, based only on a modest tweak to Medicare

26 May 2020 - President Trump used a glitzy Rose Garden address, flanked by pharmaceutical company CEOs and patient advocates, ...

Read more →

COVID-19: UK authorises anti-viral drug remdesivir

26 May 2020 - A drug treatment called remdesivir that appears to shorten recovery time for people with coronavirus is ...

Read more →

Record flu vaccines in 2020 to protect Australians

27 May 2020 - An additional two million flu vaccines will available from this week bringing the total number available in ...

Read more →

Prospective dialogue between developers and regulators makes for better evidence generation

27 May 2020 - EMA, in collaboration with other parties, has recently published two scientific articles outlining the importance of ...

Read more →

Bristol Myers Squibb receives European Commission approval for Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease

27 May 2020 - Zeposia is the only approved sphingosine-1-phosphate receptor modulator for RRMS patients with active disease. ...

Read more →

NICE issues final guidance on NHS use of Bayer's Vitrakvi

27 May 2020 - The NICE has published final guidance recommending NHS use of Bayer's Vitrakvi (larotrectinib) for a variety ...

Read more →

NICE recommends treatment for type of small-cell lung cancer

27 May 2020 - A new treatment option for patients with extensive-stage small-cell lung cancer has been approved by NICE. ...

Read more →

EMA publishes agenda for 25-28 May 2020 CHMP meeting

27 May 2020 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

EMA commissions independent research to prepare for real world monitoring of COVID-19 vaccines

27 May 2020 - EMA is engaging early with researchers to ensure that a European infrastructure will be in place to ...

Read more →

U.S. FDA approves Opdivo (nivolumab) and Yervoy (ipilimumab) combined with limited chemotherapy as first-line treatment of metastatic or recurrent non-small cell lung cancer

26 May 2020 - Approval marks sixth indication for Opdivo and Yervoy-based combinations across five types of cancer. ...

Read more →

Cellectar receives FDA fast track designation for CLR 131 in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinaemia

26 May 2020 - Cellectar Biosciences today announced the U.S. FDA has granted fast track designation for CLR 131 in lymphoplasmacytic ...

Read more →

Alnylam announces U.S. FDA has granted priority review of the lumasiran new drug application for the treatment of primary hyperoxaluria type 1

26 May 2020 - PDUFA date set for 3 December 2020. ...

Read more →